OKYO Pharma Ltd (OKYO) Actualités

OKYO Pharma CEO Interview to Air on Bloomberg TV

LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

OKYO Pharma Announces Chairman Acquires Shares

LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

OKYO Pharma Announces Chairman Acquires Shares

LONDON and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

LONDON and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage...

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use

LONDON and NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage...

Form NT 20-F - Notification of inability to timely file Form 20-F

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101

Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease

Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining...